Key Takeaways Pfizer will report Q2 results on Aug. 5, with sales and EPS estimates at $13.78B and $0.58, respectively.PFE topped earnings estimates for four straight quarters, delivering an average surprise of 43.49%.Strong sales of Vyndaqel and Padcev are expected to offset declines from Eliquis, Ibrance and Prevnar.Pfizer (PFE) will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $13.78 billion ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 01, 2025 (GLOBE NEW ...

AptarGroup (ATR) Q2 2025 Earnings Call August 01, 2025 09:00 AM ET Speaker0Ladies and gentlemen, thank you for standing by, and welcome to Aptar's twenty twenty five Second Quarter Results Conference Call. At this time, all participants are in listen only mode. Later, we will conduct a question and answer session. Introducing today's conference call is Ms. Mary Scafidas, Senior Vice President, Investor Relations and Communications.Please go ahead, Mary.Speaker1Thank you. Hello, everyone, and thanks for bein ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

LENZ Therapeutics (LENZ) Update / Briefing August 01, 2025 08:00 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the LENS Therapeutics Corporate Update Conference Call. At this time, all participants are in a listen only mode. Following prepared remarks from management, we will conduct question and answer session and instructions will follow at that time. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Dan Chief Financial Officer.Please go ahe ...

Regeneron Corporate Presentation A U G U S T 2 0 2 5 This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may di ...

Key Takeaways Adobe, Disney, Intuit, Rollins and JNJ all offer wide moat business models with strong potential in 2H2025.Each company shows solid earnings and revenue growth expectations with estimate revisions trending upward.Unique assets like AI tools, strong brands, and strategic acquisitions reinforce long-term market dominance.The wide moat strategy involves investing in companies that not only lead their industries but are also strategically fortified to maintain dominance in the future. The business ...

汇添富中证中药ETF联接(LOF)A 鹏华中证中药ETF联接C x 大大基金 链接您与财富 中药板块式比 主精品+创新两大 8月1日,中药板块持续逆势拉升,多股涨停。机构研报表示,中 药板块关注受库存周期扰动的中药OTC边际拐点。把握精品+创 新两大主线:精品中药兼具医疗价值与消费属性;创新中药在利 好政策的支持与外部环境正向刺激下正在逐渐迎来收获期。 | 中药品牌 | 华润三九 | 以岭药业 | 东阿阿胶 | 太极集团 | | --- | --- | --- | --- | --- | | OTC | 康 恩 贝 | 江中药业 | 昆药集团 | 马 应 龙 | | 精品中药 | 同 仁 堂 | 东阿阿胶 | 健民集团 | 云南白药 | | | L | 誉 远 片 仔 廣 | | | | 创新药 | 中药 康缘药业 珍 宝 岛 济川药业 | | 天 士 力 以岭药业 云南白药 | | 相关基金 前海开源中药股票A 中国 中国 4月 三 华金 证券 表示，中药板块当前估值、机构持仓均处于历史低位。短期，库存拐点+线上渠道 突破是核心催化；中期，成本改善+高股息提供安全边际；长期，政策基药、 创新药 与需求 (老 ...

MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access PathwaySOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK’s Medi ...

SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (“Artelo” or the “Company”) (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinica ...